Predictive model of pro- and anti-angiogenic factors involved in breast cancer
乳腺癌中促血管生成因子和抗血管生成因子的预测模型
基本信息
- 批准号:8000324
- 负责人:
- 金额:$ 4.76万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-09-15 至 2013-02-14
- 项目状态:已结题
- 来源:
- 关键词:Angiogenesis Inducing AgentsAngiogenesis InhibitorsAngiogenic FactorAngiogenic PeptidesBindingBlood PlateletsBlood VesselsBlood capillariesComputer SimulationDevelopmentDiagnosisEquilibriumExtracellular Matrix ProteinsFunctional disorderGrowthGrowth FactorMalignant NeoplasmsMembraneModelingNeoplasm MetastasisPathway interactionsProcessResearchRoleSimulateTestingTherapeuticThrombospondin 1Tumor AngiogenesisVascular Endothelial Growth FactorsVascular blood supplyVascularizationWomanangiogenesisbasecancer cellcancer therapycapillaryinhibitor/antagonistmalignant breast neoplasmnew growthpredictive modelingpromoterpublic health relevanceresearch studyresponsetumor
项目摘要
DESCRIPTION (provided by applicant): Cancer development, invasion, and metastasis is largely dependent on angiogenesis, the formation of new capillaries from pre-existing blood vessels, and this process is exquisitely regulated by a balance of pro- and anti-angiogenic factors. Stimulators of angiogenesis include growth factors, such as vascular endothelial growth factor (VEGF), a key promoter of vascular growth. Additionally, membrane-bound or extracellular matrix proteins, including thrombospondin-1 (TSP1), function as endogenous inhibitors of angiogenesis. In the case of cancer, the balance is altered, leading to a state of hyper-vascularization and allowing the tumor to establish its own blood supply. A quantitative description of the dynamic equilibrium of promoters and inhibitors of vascular growth would aid in our understanding of tumor angiogenesis and provide a platform to test cancer therapies that control this process. The proposed research aims to develop an experiment-based computational model of breast cancer angiogenesis that incorporates endogenous pro- and anti-angiogenic pathways (Aim 1). The model will be used to probe the mechanism by which TSP1 inhibits vascular growth and quantify the role of platelets in angiogenesis (Aim 2). Additionally, the model will simulate and predict the angiogenic response to breast cancer therapies, including VEGF-neutralizing agents and TSP1-derived anti- angiogenic peptides (Aim 3). This research will further our understanding of angiogenesis-related pathophysiology and facilitate the development and optimization of cancer therapies that inhibit tumor angiogenesis.
PUBLIC HEALTH RELEVANCE: More than 180,000 women are diagnosed with breast cancer each year. Cancer development, leading to invasion and metastasis, is largely governed by the cancer cells' ability to promote the growth of new blood vessels from pre-existing ones, a process called angiogenesis. This project aims to develop a quantitative model to study the balance of promoters and inhibitors of angiogenesis and apply the model to aid in the development of cancer therapeutics.
描述(由申请人提供):癌症的发展、侵袭和转移在很大程度上依赖于血管生成,即从预先存在的血管形成新的毛细血管,并且该过程受到促血管生成因子和抗血管生成因子的平衡的精细调节。血管生成的刺激物包括生长因子,例如血管内皮生长因子(VEGF),血管生长的关键促进剂。此外,膜结合或细胞外基质蛋白,包括血小板反应蛋白-1(TSP 1),作为血管生成的内源性抑制剂发挥作用。在癌症的情况下,平衡被改变,导致过度血管化的状态,并允许肿瘤建立自己的血液供应。血管生长的促进剂和抑制剂的动态平衡的定量描述将有助于我们理解肿瘤血管生成,并提供一个平台来测试控制这一过程的癌症治疗。该研究旨在开发一种基于实验的乳腺癌血管生成计算模型,该模型包含内源性促血管生成和抗血管生成途径(目的1)。该模型将用于探测TSP 1抑制血管生长的机制,并量化血小板在血管生成中的作用(目的2)。此外,该模型将模拟和预测对乳腺癌治疗的血管生成反应,包括VEGF中和剂和TSP 1衍生的抗血管生成肽(Aim 3)。这项研究将进一步加深我们对血管生成相关病理生理学的理解,并促进抑制肿瘤血管生成的癌症治疗方法的开发和优化。
公共卫生相关性:每年有超过180,000名妇女被诊断患有乳腺癌。癌症的发展,导致入侵和转移,在很大程度上取决于癌细胞促进新血管从现有血管生长的能力,这一过程称为血管生成。本项目旨在开发一个定量模型来研究血管生成促进剂和抑制剂的平衡,并将该模型应用于癌症治疗的开发。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Stacey Deleria Finley其他文献
Stacey Deleria Finley的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Stacey Deleria Finley', 18)}}的其他基金
Modeling based design of chimeric antigen receptors for Natural Killer cell-based immunotherapy
用于基于自然杀伤细胞的免疫治疗的嵌合抗原受体的基于建模的设计
- 批准号:
10701754 - 财政年份:2022
- 资助金额:
$ 4.76万 - 项目类别:
Modeling based design of chimeric antigen receptors for Natural Killer cell-based immunotherapy
用于基于自然杀伤细胞的免疫治疗的嵌合抗原受体的基于建模的设计
- 批准号:
10557760 - 财政年份:2022
- 资助金额:
$ 4.76万 - 项目类别:
Multiscale systems biology modeling to exploit tumor-stromal metabolic crosstalk in colorectal cancer
多尺度系统生物学模型利用结直肠癌中的肿瘤间质代谢串扰
- 批准号:
10251884 - 财政年份:2018
- 资助金额:
$ 4.76万 - 项目类别:
Predictive model of pro- and anti-angiogenic factors involved in breast cancer
乳腺癌中促血管生成因子和抗血管生成因子的预测模型
- 批准号:
8165999 - 财政年份:2010
- 资助金额:
$ 4.76万 - 项目类别:
Predictive model of pro- and anti-angiogenic factors involved in breast cancer
乳腺癌中促血管生成因子和抗血管生成因子的预测模型
- 批准号:
8305964 - 财政年份:2010
- 资助金额:
$ 4.76万 - 项目类别:
相似海外基金
Development of Novel Lung Cancer Therapy Using Tumor-Specific Angiogenesis Inhibitors and Drug Repositioning
使用肿瘤特异性血管生成抑制剂和药物重新定位开发新型肺癌疗法
- 批准号:
21H03019 - 财政年份:2021
- 资助金额:
$ 4.76万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Development of biomarkers related to drug resistance of angiogenesis inhibitors
血管生成抑制剂耐药性相关生物标志物的开发
- 批准号:
20K08542 - 财政年份:2020
- 资助金额:
$ 4.76万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Structural and Functional Studies of Brain Angiogenesis Inhibitors (BAIs/ADGRBs)
脑血管生成抑制剂 (BAIs/ADGRB) 的结构和功能研究
- 批准号:
9813883 - 财政年份:2019
- 资助金额:
$ 4.76万 - 项目类别:
Elucidation of proteinuria expression mechanism by angiogenesis inhibitors and research on adverse effect avoidance
血管生成抑制剂蛋白尿表达机制的阐明及不良反应避免的研究
- 批准号:
17K08457 - 财政年份:2017
- 资助金额:
$ 4.76万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Evaluation of cardiotoxicity and elucidation of cardiotoxic molecular mechanisms in cancer patients receiving angiogenesis inhibitors
接受血管生成抑制剂的癌症患者的心脏毒性评估和心脏毒性分子机制的阐明
- 批准号:
26461102 - 财政年份:2014
- 资助金额:
$ 4.76万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Minimally invasive response evaluation in vivo for the dual therapy of the angiogenesis inhibitors
血管生成抑制剂双重治疗的体内微创疗效评价
- 批准号:
23591763 - 财政年份:2011
- 资助金额:
$ 4.76万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
ANGIOGENESIS INHIBITORS IN THE MULTIMODAL TREATMENT OF PEDIATRIC SOLID TUMORS
血管生成抑制剂在小儿实体瘤多模式治疗中的应用
- 批准号:
8309814 - 财政年份:2011
- 资助金额:
$ 4.76万 - 项目类别:
Discovery and Investigation of Novel Angiogenesis Inhibitors Among Existing Drugs
现有药物中新型血管生成抑制剂的发现和研究
- 批准号:
7351352 - 财政年份:2008
- 资助金额:
$ 4.76万 - 项目类别:
Discovery and Investigation of Novel Angiogenesis Inhibitors Among Existing Drugs
现有药物中新型血管生成抑制剂的发现和研究
- 批准号:
8002099 - 财政年份:2008
- 资助金额:
$ 4.76万 - 项目类别:
Discovery and Investigation of Novel Angiogenesis Inhibitors Among Existing Drugs
现有药物中新型血管生成抑制剂的发现和研究
- 批准号:
7537218 - 财政年份:2008
- 资助金额:
$ 4.76万 - 项目类别:














{{item.name}}会员




